Oats (Avena sativa) reduce atherogenesis in LDL-receptor-deficient mice

Atherosclerosis. 2010 Sep;212(1):93-9. doi: 10.1016/j.atherosclerosis.2010.05.001. Epub 2010 May 11.

Abstract

Aim: The cholesterol-lowering properties of oats, largely ascribed to its contents of soluble fibers, beta-glucans, are well established, whereas effects on atherogenesis are less well elucidated. Oats also contains components with reported antioxidant and anti-inflammatory effects that may affect atherogenesis. In this work we examined effects of oat bran on plasma cholesterol, markers of inflammation, eNOS expression and development of atherosclerosis in LDL-receptor-deficient (LDLr(-/-)) mice.

Methods and results: Female LDLr(-/-) mice were fed Western diet+/-oat bran. Two concentrations of oat bran (40 and 27%) were compared regarding effects on plasma lipids. There was a dose-dependent reduction of plasma cholesterol by 42 and 20% with 40 and 27% oat bran, respectively. Both concentrations also lowered plasma triglycerides (by 45 and 33%) and relative levels of plasma LDL+VLDL. The reduction of plasma lipids was accompanied by increased faecal excretion of cholesterol and bile acids. Oat bran (40%) efficiently reduced atherosclerotic lesion area in the descending aorta (-77%) and aortic root (-33%). Plasma levels of fibrinogen and soluble vascular cell adhesion molecule-1 (VCAM-1) were significantly lower, and immunofluorescence of aortic sections revealed a 75% lower expression of VCAM-1 in oat-fed mice. The expression of eNOS protein in the aortic wall was increased in mice fed oat bran.

Conclusions: Oat bran supplemented to a Western diet lowers plasma cholesterol, reduces levels of some inflammatory markers, increases eNOS expression and inhibits atherosclerotic lesion development in LDLr(-/-) mice. It remains to be investigated which components in oats contribute to these effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / enzymology
  • Aorta, Thoracic / pathology
  • Aortic Diseases / genetics
  • Aortic Diseases / metabolism
  • Aortic Diseases / pathology
  • Aortic Diseases / prevention & control*
  • Atherosclerosis / genetics
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Atherosclerosis / prevention & control*
  • Avena*
  • Bile Acids and Salts / metabolism
  • Biomarkers / blood
  • Body Weight
  • Cholesterol / blood
  • Dietary Fiber / administration & dosage*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Eating
  • Feces / chemistry
  • Female
  • Fibrinogen / metabolism
  • Hypolipidemic Agents / administration & dosage*
  • Inflammation Mediators / blood
  • Lipoproteins, LDL / blood
  • Lipoproteins, VLDL / blood
  • Mice
  • Mice, Knockout
  • Nitric Oxide Synthase Type III / metabolism
  • Receptors, LDL / deficiency*
  • Receptors, LDL / genetics
  • Time Factors
  • Triglycerides / blood
  • Vascular Cell Adhesion Molecule-1 / blood

Substances

  • Anti-Inflammatory Agents
  • Bile Acids and Salts
  • Biomarkers
  • Dietary Fiber
  • Hypolipidemic Agents
  • Inflammation Mediators
  • Lipoproteins, LDL
  • Lipoproteins, VLDL
  • Receptors, LDL
  • Triglycerides
  • Vascular Cell Adhesion Molecule-1
  • Fibrinogen
  • Cholesterol
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse